GeneDx reports Q4 adjusted EPS 14c, consensus 12c

Reports Q4 revenue $121.0M, consensus $120.44M. “The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx (WGS) is uniquely positioned to deliver for patients, clinicians, and partners – and our results demonstrate that. Our team is executing at the highest level, our platform continues to scale, and GeneDx InfinityTM gives us a compounding data advantage that strengthens with every test we run,” said Katherine Stueland, CEO. “The business has never been in a better position for continued growth and success. As we enter 2026, we will layer new growth drivers onto an already powerful foundation – expanding into large, underpenetrated markets where patients are waiting for a diagnosis that GeneDx can provide today.”